BlackBerry Ltd (NASDAQ:BBRY)’s official Twitter account has just deleted a tweet that was sent out via iPhone. its top competitor. BlackBerry tweeted a message Tuesday afternoon promoting its new BlackBerry Classic phone and urging consumers to “keep up with the conversation” on Twitter. On Tuesday shares of BlackBerry Ltd (NASDAQ:BBRY) closed at $9.71. Company’s sales growth for last 5 years was 43.43% and EPS growth for next 5 years is recorded as 5.00%.
Transocean LTD (NYSE:RIG) said it would send seven of its older rigs to the scrapyard. Transocean Ltd. (NYSE:RIG) in last trading activity increased 0.06% to close at $15.52. Company weekly performance is -5.71% while its quarterly performance stands at -44.89%. Transocean Ltd. (NYSE:RIG) is -65.49% away from its 52 week high.
Research Frontiers, Inc. (NASDAQ:REFR) has a short ratio of 43.62. Higher the ratio, the more pressurized the stock will be, lower the ratio, lesser the duress on the stock. The short interest has seen a change of -3.09% in the past month. The 3-month change in short interest was measured at -8.75%. On last trading day Research Frontiers Inc. (NASDAQ:REFR) remains unchanged to close at $5.14. Its volatility for the week is 2.75% while volatility for the month is 3.06%. REFR’s sales growth for past 5 years was 5.30% and its EPS growth for past 5 years was -8.00%. Research Frontiers Inc. (NASDAQ:REFR) monthly performance is -2.65%.
Yelp, Inc. (NYSE:YELP), SVP Laurence Wilson sold 1,250 shares of Yelp stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $53.52, for a total transaction of $66,900.00. On Tuesday shares of Yelp, Inc. (NYSE:YELP) closed at $53.18. Company’s sales growth for last 5 years was 80.70% and EPS growth for next 5 years is recorded as 50.60%.
Drugmaker Merck & Co. Inc. (NYSE:MRK) is ratcheting up its race with rival Bristol-Myers Squibb Co. for leadership in one of today’s hottest research areas, immuno-oncology, which harnesses the immune system to fight cancer. Merck said Monday that by midyear it will apply for approval of its melanoma drug, Keytruda, for fighting lung cancer. Merck & Co. Inc. (NYSE:MRK) in last trading activity fell -0.18% to close at $62.19. Company weekly performance is 3.10% while its quarterly performance stands at 11.61%. Merck & Co. Inc. (NYSE:MRK) is -2.06% away from its 52 week high.